Yondelis en la lista de aprobaciones de Thomson Scientific Publishes , publicada hoy .

The first of two potential treatments for cancer on the list of notabledrugs gaining approval this quarter is Yondelis, developed by PharmaMar forpatients who have not responded to previous regimens in their treatment ofsoft tissue sarcoma. Yondelis is the first approved product from PharmaMar, aSpanish biotech specializing in cancer drugs derived from marine organisms andhas Orphan Drug status in both the EU and U.S., securing extended protectionagainst generic competition.

Aplidin un nuevo agente contra el cáncer marina muy particular, con un retraso en neuromusculares toxicidad con prometedora actividad antitumoral.

Revista Current Pharmaceutical Design de Noviembre 2007 .

Novel Marine-Derived Anti-Cancer Agents.

Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison.

Author: Adrian, Thomas E.1

Source: Current Pharmaceutical Design, Volume 13, Number 33, November 2007 , pp. 3417-3426(10)

Publisher: Bentham Science Publishers

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled

Yondelis en la Revista Cell Proliferation del mes de Diciembre 2007 :

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach

Zeltia ampliacion de capital de 2.202.181 nuevas acciones a 7,03 euros subscritas por el Santander .